April Journal-2009.p65 - Association of Biotechnology and Pharmacy

More documents

Recommendations

Info

Current Trends in Biotechnology and Pharmacy Vol. 3 (2) 181-187, April 2009. ISSN 0973-8916 186 the major genetic determinant of polymorphic activity in humans. Pharmacogenetics, 10: 415-424. Fig. 1: Electrophoretogram of Dde I digested PCR product generated by amplification of genomic DNA using CYP3A5*3 gene specific primers. Lane # 1: 100 bp DNA ladder lane # 2: 3/3Genotype lane # 3,: 1/3Genotype lane # 4: 1/1Genotype Fig. 2: Electrophoretogram of Dde I digested PCR product generated by amplification of genomic DNA using CYP3A5*6 gene specific primers. Lane # 1-4: 1/1 lane # 5: Uncut band lane # 6,: 100 bp DNA ladder Reference 1. Paulussen A., Lavrijsen K., Bohets H., Hendrickx J., Verhasselt P., Luyten W., Konings F. and Armstrong M. (2000). Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute 2. Gellner K., Eiselt R., Hustert E., Arnold H., Koch I., Haberl M., Deglmann CJ., Burk O., Buntefuss D., Escher S., Bishop C., Koebe HG., Brinkmann U., Klenk HP., Kleine K., Meyer UA. and Wojnowski L. (2001). Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11: 111-121. 3. Jounaidi Y., Guzelian PS., Maurel P. and Vilarem MJ. (1994). Sequence of the 5- prime-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem. Biophys Res Commun, 205: 1741-1747. 4. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins PB., Daly A., Wrighton SA., Hall SD., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski MS. and Schuetz E. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Gene, 27: 383- 391. 5. Park SY., Kang YS., Jeong MS., Yoon HK. and Han KO. (2008). Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. Pharmacogenetics, 33 (1): 61-65. 6. Liu TC., Lin SF., Chen TP. and Chang JG. (2001). Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep,9(2):327- 9. 7. Nuremberg JI. and Lahari D KJr. (1991). A rapid non-enzymatic method for the Surekha et al
Current Trends in Biotechnology and Pharmacy Vol. 3 (2) 181-187, April 2009. ISSN 0973-8916 preparation of HMW DNA from blood RFLP studies. Nucleic Acid Research, 19: 5444. 8. Ta-Chih Liu., Sheng-Fung Lin., Tyen-Po Chen. and Jan-Goeth Chang. (2002). Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncology reports, 9: 327-329. 9. Gillam EMJ., Guo Z., Ueng YF., Yamazaki H., Cock I., Reilly PE. and Hooper WD. and Guengerich FP. (1995). Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5’ modification, purification, spectral charecterization, reconstitution condition and catalytic activities. Arch Biochem Biophys, 318: 374-384. 10. Wojnowski L., Hustert E., Klein K., Goldhammer M., Haberl M., Kiechheiner J., Koch L., Klattig J., Zanger U. and Brock moller J.Re. (2002). Modification of clinical 187 presentation of prostrate tumors by a novel genetic variant in CYP2A4.J Natl Cancer Inst, 94:630-631. 11. Gervasini G., Marti E., Ladero M., Pizarro R., Sastre J., Martinez C., Gracia M., Diaz- Rubio M. and Agundez AG. (2007). Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer, 7: 118. 12. Wilkinson GR. (2004). Genetic variabilityin cytochrome P4503A5 and invivo cytochrome cytochrome P4503A activity: some answers but still questions. Clin Pharmacol Ther, 76:99-103. 13. Nogal A., Coelho A., Araujo A., Azevedo I., Faria A., Soares M., Catarino R. and Medeiros R. (2007) CYP3A5*3 genotypes and advanced non-small cell lung cancer development. Journal of clinical Oncology, 25(18S): 21030. CYP3A5*3 and CYP3A5*6 Polymorphisms and Breast Cancer
Page 2 and 3:
Current Trends in Biotechnology and
Page 4 and 5:
Association of Biotechnology and Ph
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31: Current Trends in Biotechnology and
Page 50: Current Trends in Biotechnology and
show all

April Journal-2009.p65 - Association of Biotechnology and Pharmacy

Create successful ePaper yourself

Delete template?

Save as template?